Genocea harnesses the power of T cells to discover life-changing vaccines and immunotherapies. While traditional discovery methods have largely used in silico methods to propose T cell targets, or antigens, we use ATLASTM, our proprietary technology platform, to identify clinically relevant T cell antigens based on patients’ own T cell immune responses to their cancers. We are using ATLAS’s superiority in antigen identification to develop neoantigen cancer vaccines with our lead candidate, GEN-009, expected to enter clinical development in early 2018.
|Bank Name||Genocea Biosciences, Inc.|
|Industry||Biotechnology: Biological Products|
|CEO||Mr. William D. Clark M.B.A.|